PMID- 23050762
OWN - NLM
STAT- MEDLINE
DCOM- 20130425
LR  - 20151119
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
VI  - 11
IP  - 11
DP  - 2012 Nov 2
TI  - iTRAQ-based quantitative protein expression profiling and MRM verification of 
      markers in type 2 diabetes.
PG  - 5527-39
LID - 10.1021/pr300798z [doi]
AB  - The pathogenesis of Type 2 diabetes mellitus (T2DM) is complex owing to molecular 
      heterogeneity in the afflicted population. Current diagnostic methods rely on 
      blood glucose measurements, which are noninformative with respect to progression 
      of the disease to other associated pathologies. Thus, predicting the risk and 
      development of T2DM-related complications, such as cardiovascular disease, 
      remains a major challenge. We have used a combination of quantitative methods for 
      characterization of circulating serum biomarkers of T2DM using a cohort of 
      nondiabetic control subjects (n = 76) and patients diagnosed with T2DM (n = 106). 
      In this case-control study, the samples were randomly divided as training and 
      validation data sets. In the first step, iTRAQ (isobaric tagging for relative and 
      absolute quantification) based protein expression profiling was performed for 
      identification of proteins displaying a significant differential expression in 
      the two study groups. Five of these protein markers were selected for validation 
      using multiple reaction-monitoring mass spectrometry (MRM-MS) and further 
      confirmed with Western blot and QPCR analysis. Functional pathway analysis 
      identified perturbations in lipid and small molecule metabolism as well as 
      pathways that lead to disruption of glucose homeostasis and blood coagulation. 
      These putative biomarkers may be clinically useful for subset stratification of 
      T2DM patients as well as for the development of novel therapeutics targeting the 
      specific pathology.
FAU - Kaur, Prabhjit
AU  - Kaur P
AD  - Department of Oncology, Lombardi Comprehensive Cancer Center at Georgetown 
      University Medical Center, Washington, D.C., USA.
FAU - Rizk, Nasser M
AU  - Rizk NM
FAU - Ibrahim, Sereen
AU  - Ibrahim S
FAU - Younes, Noura
AU  - Younes N
FAU - Uppal, Arushi
AU  - Uppal A
FAU - Dennis, Kevin
AU  - Dennis K
FAU - Karve, Tejaswita
AU  - Karve T
FAU - Blakeslee, Kenneth
AU  - Blakeslee K
FAU - Kwagyan, John
AU  - Kwagyan J
FAU - Zirie, Mahmoud
AU  - Zirie M
FAU - Ressom, Habtom W
AU  - Ressom HW
FAU - Cheema, Amrita K
AU  - Cheema AK
LA  - eng
GR  - P30-CA051008/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20121023
PL  - United States
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
SB  - IM
MH  - Biomarkers/*blood
MH  - Blood Proteins/*metabolism
MH  - Chromatography, Liquid
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Humans
MH  - Real-Time Polymerase Chain Reaction
MH  - Tandem Mass Spectrometry
EDAT- 2012/10/12 06:00
MHDA- 2013/04/26 06:00
CRDT- 2012/10/12 06:00
PHST- 2012/10/12 06:00 [entrez]
PHST- 2012/10/12 06:00 [pubmed]
PHST- 2013/04/26 06:00 [medline]
AID - 10.1021/pr300798z [doi]
PST - ppublish
SO  - J Proteome Res. 2012 Nov 2;11(11):5527-39. doi: 10.1021/pr300798z. Epub 2012 Oct 
      23.